Nucleome Therapeutics Revenue and Competitors

Oxford,

Location

#9228

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Nucleome Therapeutics's estimated annual revenue is currently $8.7M per year.(i)
  • Nucleome Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Nucleome Therapeutics has 56 Employees.(i)
  • Nucleome Therapeutics grew their employee count by 40% last year.

Nucleome Therapeutics's People

NameTitleEmail/Phone
1
Chief Business OfficerReveal Email/Phone
2
CEO & Co-FounderReveal Email/Phone
3
Head FinanceReveal Email/Phone
4
VP BiologyReveal Email/Phone
5
Head PeopleReveal Email/Phone
6
VP, OperationsReveal Email/Phone
7
Director FacilitiesReveal Email/Phone
8
Chief Financial OfficerReveal Email/Phone
9
Project ManagerReveal Email/Phone
10
Principal ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Nucleome Therapeutics?

NUCLEOME THERAPEUTICS is an exciting new venture that just spun out from a decade of research at Oxford University with the aim to unlock the non-coding part of the genome to help deliver life changing treatments. We are building a passionate, creative and dedicated multi-disciplinary team of scientists with expertise in gene regulation, genomics, machine learning, data analysis and software developers, whose mission is to decode and mine the regulatory “dark matter” of the human genome to transform drug target discovery and help deliver the next generation of genetically guided therapeutics. We are building a rewarding and fun environment where people embrace creative ways of thinking, take smart risks, and feel empowered to make a difference.

keywords:N/A

N/A

Total Funding

56

Number of Employees

$8.7M

Revenue (est)

40%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nucleome Therapeutics News

2022-04-20 - Nucleome Therapeutics appoints Dr Phil Boyd as Chief ...

Oxford, UK, 21 April 2022 – Nucleome Therapeutics, ('Nucleome' or 'the Company'), a biotechnology company utilizing breakthrough technologies to...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A5739%N/A
#2
$20.9M5814%N/A
#3
$11.5M589%N/A
#4
N/A58-5%N/A
#5
$7.4M59-29%N/A